A combination of animal studies, data from a clinical trial and insights from an observational cohort suggest that, in individuals with metabolic dysfunction-associated steatohepatitis, semaglutide improves liver histology by reverting patient proteomes to better mimic the proteome of individuals without the disease.
- Maximilian Jara
- Jenny Norlin
- Lotte B. Knudsen
